Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cibinetide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.45 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.44 |
| ▸ | NMUR2 | Q9GZQ4 | 3/20 | 0.44 |
| ▸ | NMUR1 | Q9HB89 | 3/20 | 0.44 |
| ▸ | RAMP3 | O60896 | 7/20 | 0.44 |
| ▸ | CALCR | P30988 | 7/20 | 0.44 |
| ▸ | HRAS | P01112 | 1/20 | 0.42 |
| ▸ | KRAS | P01116 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cibinetide SCHEMBL29425532 | 0.88 | OPRK1 (0.49) | NMUR2 | |
| SCHEMBL34464906 | 0.87 | NMUR2 (0.47) | TFPIBECN1NMUR2NMUR1NPY1R | |
| SCHEMBL2196378 | 0.83 | NPY4R (0.42) | BECN1NPY1RNPY4RNPY5R | |
| SCHEMBL29829461 | 0.82 | MAPK8 (0.51) | NMUR2NMUR1RAMP3CALCRKDM1A | |
| SCHEMBL29727699 | 0.81 | OPRL1 (0.43) | TFPIBECN1 | |
| SCHEMBL29486953 | 0.81 | BACE1 (0.49) | NPY1RNPY4RNPY5R | |
| SCHEMBL2195684 | 0.80 | HDAC3 (0.41) | TFPIBECN1NMUR2NMUR1NPY1R | |
| SCHEMBL29829129 | 0.80 | CXCR4 (0.40) | KDM1A | |
| SCHEMBL2183043 | 0.80 | OPRK1 (0.42) | BECN1NPY1RNPY4RNPY5R | |
| SCHEMBL31031601 | 0.79 | NPY4R (0.49) | TFPINPY1RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | claimed |
| US-20250312463-A1 | AUGMENTED PEPTIDE COMPOSITIONS AND METHODS | Neo7Bioscience, Inc. (US) | 2025-10-09 | — | — | US | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| CN-119206946-A | Electricity exchange management system and method | 深圳即刻换电数字信息有限公司 | 2024-12-27 | — | — | CN | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2024222890-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-31 | — | — | WO | claimed |
| EP-3720468-B1 | TISSUE REPAIR | UNIV SUSSEX (GB) | 2024-10-30 | — | — | EP | claimed |
| CN-117379566-A | Application of FBXL12 gene and coded protein thereof | 同济大学 | 2024-01-12 | — | — | CN | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230173142-A1 | BALLISTIC DELIVERY TO MULTILAYERED TISSUES AND RELATED PARTICLES, COMPOSITIONS, METHODS AND SYSTEMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-06-08 | — | — | US | claimed |
| US-11596668-B2 | Tissue repair | THE UNIVERSITY OF SUSSEX (GB) | 2023-03-07 | — | — | US | claimed |
| CN-111150837-B | Application of EPO in medicines for resisting staphylococcus aureus infection | 中国人民解放军陆军军医大学 | 2022-07-12 | — | — | CN | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4735449-A1 | TETRACYCLIC COMPOUNDS CONTAINING A FUSED INDOLE FOR TREATING APOL1-MEDIATED CHRONIC KIDNEY DISEASE | OmniAB, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20220098187-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-03-31 | — | — | US | disclosed |
| CN-114127089-A | Recombinant adeno-associated virus and use thereof | 再生生物股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-110177527-B | Device and method for adjusting insertion depth of needle for medicament delivery | 科尼尔赛德生物医学公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098187-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | TFPI 398/4885BECN1 3264/4885NMUR2 4629/4885 |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | S100A8, TP53, AQP1 | TFPI 1791/4885BECN1 2653/4885NMUR2 2997/4885 |
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | GLP1R, GIPR, GPR119 | TFPI 4101/4885BECN1 1820/4885NMUR2 418/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | TFPI 986/4885BECN1 3708/4885NMUR2 666/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | TFPI 2151/4885BECN1 2137/4885NMUR2 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.